UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-03 | 0.51 | 0.51 |
| Q1 2022 | 2022-05-04 | 0.64 | 0.64 |
| Q4 2021 | 2022-02-24 | 0.97 | 0.97 |
| Q3 2021 | 2021-11-03 | 0.72 | 0.72 |
| Q2 2021 | 2021-08-03 | 0.77 | 0.77 |
| Q1 2021 | 2021-05-04 | 0.53 | 0.53 |
| Q4 2020 | 2021-02-25 | 0.87 | 0.87 |
| Q3 2020 | 2020-10-29 | 0.68 | 2.94 |
| Q2 2020 | 2020-08-06 | 0.12 | -0.17 |
| 2016-07-01 | Reiterated Rating | Mizuho | Outperform | $64.00 |
| 2016-07-01 | Downgrade | Brean Capital | Buy to Hold | |
| 2016-06-28 | Initiated Coverage | BMO Capital Markets | Underperform | $36.00 |
| 2016-06-22 | Reiterated Rating | Wedbush | Outperform | $105.00 |
| 2016-06-22 | Reiterated Rating | Mizuho | Buy | |
| 2016-05-26 | Reiterated Rating | Mizuho | Buy | |
| 2016-05-25 | Lower Price Target | Wedbush | Outperform | $113.00 to $105.00 |
| 2016-05-04 | Reiterated Rating | Wedbush | Outperform | $113.00 |
| 2016-05-03 | Lower Price Target | Mizuho | Buy | $71.00 to $64.00 |
| 2016-04-20 | Reiterated Rating | Wedbush | Outperform | $113.00 |
| 2016-04-20 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-04-19 | Initiated Coverage | Mizuho | Buy | $79.00 |
| 2016-03-23 | Reiterated Rating | Wedbush | Outperform | $113.00 |
| 2016-02-29 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-02-28 | Reiterated Rating | Nomura | Buy | $100.00 |
| 2016-02-28 | Reiterated Rating | Nomura Holdings Inc. | Buy | $100.00 |
| 2016-02-26 | Reiterated Rating | Brean Capital | Buy | $92.00 to $75.00 |
| 2016-02-26 | Lower Price Target | Wedbush | Outperform | $123.00 to $113.00 |
| 2016-02-25 | Reiterated Rating | Wedbush | Buy | $123.00 |
| 2016-01-29 | Upgrade | Bank of America | Neutral to Buy | $75.00 |
| 2016-01-29 | Upgrade | Bank of America Corp. | Neutral to Buy | $75.00 |
| 2016-01-27 | Reiterated Rating | Piper Jaffray | Overweight | $93.00 |
| 2016-01-27 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $93.00 |
| 2016-01-20 | Reiterated Rating | Wedbush | Outperform | $123.00 |
| 2016-01-09 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-01-06 | Reiterated Rating | JMP Securities | Mkt Outperform | $92.00 |
| 2016-01-05 | Initiated Coverage | JMP Securities | Outperform | $92.00 |
| 2016-01-04 | Reiterated Rating | Wedbush | Outperform | $123.00 |
| 2015-12-29 | Reiterated Rating | Wedbush | Buy | |
| 2015-12-23 | Reiterated Rating | Wedbush | Outperform | $123.00 |
| 2015-12-23 | Reiterated Rating | Brean Capital | Buy | $92.00 |
| 2015-12-21 | Reiterated Rating | Nomura | Buy | $90.00 to $100.00 |
| 2015-12-16 | Reiterated Rating | Wedbush | Outperform | $113.00 to $123.00 |
| 2015-12-15 | Reiterated Rating | Nomura | Buy | $90.00 to $100.00 |
| 2015-12-15 | Reiterated Rating | Canaccord Genuity | Buy | $78.00 |
| 2015-12-15 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-12-15 | Reiterated Rating | Brean Capital | Buy | |
| 2015-11-25 | Reiterated Rating | Wedbush | Outperform | $113.00 |
| 2015-11-09 | Reiterated Rating | Leerink Swann | Market Perform | $52.00 |
| 2015-11-03 | Reiterated Rating | Canaccord Genuity | Buy | $78.00 |
| 2015-10-27 | Initiated Coverage | Brean Capital | Buy | $92.00 |
| 2015-10-27 | Reiterated Rating | Wedbush | Buy | $106.00 to $113.00 |
| 2015-10-27 | Reiterated Rating | Canaccord Genuity | Buy | $76.00 |
| 2015-10-27 | Reiterated Rating | Nomura | Buy | $90.00 |
| 2015-10-18 | Reiterated Rating | Nomura | Buy | $90.00 |
| 2015-10-06 | Reiterated Rating | Leerink Swann | Market Perform | $69.00 to $48.00 |
| 2015-09-29 | Initiated Coverage | Nomura | Buy | $90.00 |
| 2015-09-24 | Reiterated Rating | Barclays | Buy | |
| 2015-09-24 | Reiterated Rating | Barclays PLC | Buy | |
| 2015-09-23 | Reiterated Rating | Wedbush | Buy | $106.00 |
| 2015-09-10 | Reiterated Rating | Canaccord Genuity | Buy | $76.00 |
| 2015-09-10 | Reiterated Rating | Piper Jaffray | Buy | $89.00 |
| 2015-08-19 | Reiterated Rating | Wedbush | Outperform | $106.00 |
| 2015-08-02 | Reiterated Rating | Barclays | Buy | |
| 2015-07-31 | Reiterated Rating | Leerink Swann | Hold | $86.00 to $69.00 |
| 2015-07-31 | Lower Price Target | Barclays | Overweight | $115.00 to $85.00 |
| 2015-07-31 | Reiterated Rating | Brean Capital | Buy | $92.00 |
| 2015-07-31 | Upgrade | Bank of America | Underperform to Neutral | $70.00 to $69.00 |
| 2015-07-27 | Reiterated Rating | Jefferies Group | Buy | $81.00 to $72.00 |
| 2015-07-22 | Reiterated Rating | Wedbush | Buy | $116.00 |
| 2015-06-25 | Reiterated Rating | Wedbush | Buy | |
| 2015-06-24 | Lower Price Target | Wedbush | Outperform | $127.00 to $116.00 |
| 2015-06-19 | Initiated Coverage | Leerink Swann | Market Perform | $86.00 |
| 2015-05-28 | Reiterated Rating | Brean Capital | Buy | $92.00 |
| 2015-05-20 | Set Price Target | Wedbush | Buy | $127.00 |
| 2015-05-09 | Reiterated Rating | Jefferies Group | Buy | $113.00 to $81.00 |
| 2015-04-30 | Lower Price Target | Canaccord Genuity | Buy | $128.00 to $89.00 |
| 2015-04-30 | Reiterated Rating | Brean Capital | Buy | $121.00 to $92.00 |
| 2015-04-16 | Set Price Target | Wedbush | Buy | $127.00 |
| 2015-03-24 | Reiterated Rating | Canaccord Genuity | Buy | $128.00 |
| 2015-03-04 | Lower Price Target | Brean Capital | Buy | $135.00 to $121.00 |
| 2015-03-03 | Lower Price Target | Barclays | Overweight | $127.00 to $115.00 |
| 2015-03-03 | Lower Price Target | Canaccord Genuity | Buy | $163.00 to $128.00 |
| 2015-03-02 | Boost Price Target | Barclays | Overweight | $117.00 to $127.00 |
| 2015-02-26 | Downgrade | Bank of America | Neutral to Underperform | $112.00 to $110.00 |
| 2015-02-25 | Set Price Target | Canaccord Genuity | Buy | $163.00 to $128.00 |
| 2015-02-25 | Set Price Target | Piper Jaffray | Buy | $136.00 |
| 2015-02-25 | Set Price Target | Wedbush | Outperform | $130.00 to $133.00 |
| 2015-02-24 | Boost Price Target | Brean Capital | Buy | $111.00 to $135.00 |
| 2015-02-11 | Boost Price Target | Canaccord Genuity | Buy | $114.00 to $143.00 |
| 2015-02-11 | Set Price Target | Wedbush | Buy | $130.00 |
| 2015-01-30 | Boost Price Target | Goldman Sachs | $126.00 | |
| 2015-01-30 | Boost Price Target | Goldman Sachs Group Inc. | $126.00 | |
| 2015-01-20 | Boost Price Target | Barclays | Overweight | $107.00 to $117.00 |
| 2015-01-08 | Reiterated Rating | Brean Capital | Buy | $111.00 |
| 2014-10-31 | Downgrade | Bank of America | Buy to Neutral | |
| 2014-08-01 | Boost Price Target | Wedbush | $98.00 to $110.00 | |
| 2014-08-01 | Boost Price Target | Canaccord Genuity | $114.00 | |
| 2014-08-01 | Reiterated Rating | Jefferies Group | Buy | $86.00 to $109.00 |
| 2014-07-31 | Boost Price Target | Brean Capital | Buy | $86.00 to $111.00 |
| 2014-07-17 | Reiterated Rating | Bank of America | Positive | |
| 2014-07-16 | Boost Price Target | Barclays | Overweight | $85.00 to $107.00 |
| 2014-06-27 | Initiated Coverage | Canaccord Genuity | Buy | $109.00 |
| 2014-06-17 | Initiated Coverage | JMP Securities | Market Perform | |
| 2014-06-02 | Initiated Coverage | Goldman Sachs | Buy | $93.00 |
| 2014-05-15 | Reiterated Rating | Jefferies Group | Buy | $81.00 |
| 2014-05-07 | Reiterated Rating | Jefferies Group | Buy | $81.00 |
| 2014-05-02 | Boost Price Target | Jefferies Group | $81.00 to $86.00 | |
| 2014-04-29 | Reiterated Rating | Jefferies Group | Buy | $81.00 |
| 2014-04-21 | Initiated Coverage | Jefferies Group | Buy | $81.00 |
| 2014-04-21 | Initiated Coverage | Bank of America | Buy | |
| 2014-04-01 | Upgrade | Piper Jaffray | Neutral to Overweight | $75.00 to $84.00 |
| 2014-03-18 | Initiated Coverage | National Alliance Securities | Buy | $109.41 |
| 2013-11-04 | Reiterated Rating | Wedbush | Buy | $59.00 |
| 2013-11-04 | Boost Price Target | Jefferies Group | Buy | $58.00 to $60.00 |
| 2013-11-01 | Boost Price Target | Barclays | Overweight | $56.00 to $60.00 |
| 2013-10-03 | Boost Price Target | Wedbush | Outperform | $43.00 to $59.00 |
| 2013-10-03 | Boost Price Target | Brean Capital | Buy | $44.00 to $59.00 |
| 2013-09-20 | Boost Price Target | Barclays | Overweight | $40.00 to $43.00 |
| 2011-03-17 | Initiated | Brean Murray | Buy | $20 |
| 2011-03-16 | Initiated | Wedbush | Outperform | $19 |
| 2016-07-01 | Reiterated Rating | Mizuho | Outperform | $64.00 |
| 2016-07-01 | Downgrade | Brean Capital | Buy to Hold | |
| 2016-06-28 | Initiated Coverage | BMO Capital Markets | Underperform | $36.00 |
| 2016-06-22 | Reiterated Rating | Wedbush | Outperform | $105.00 |
| 2016-06-22 | Reiterated Rating | Mizuho | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PCRX 230 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 7.15M |
| Vanguard Group, Inc | 4.87M |
| MACQUARIE GROUP LTD | 2.93M |
| BlackRock Fund Advisors | 1.92M |
| BAILLIE GIFFORD & CO | 1.85M |
| RENAISSANCE TECHNOLOGIES LLC | 1.75M |
| STATE STREET CORP | 1.70M |
| ARMISTICE CAPITAL, LLC | 1.59M |
| LOOMIS SAYLES & CO L P | 1.44M |
| Invesco Ltd. | 1.14M |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.13M |
| Clearbridge Investments, LLC | 1.13M |
| Rock Springs Capital Management LP | 1.02M |
| WELLINGTON MANAGEMENT CO LLP | 0.96M |
| BlackRock Institutional Trust Company, N.A. | 0.95M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Wicki Andreas | 3.07% (1100100) | PCRX / |
| Sanderling Venture Partners VI LP | 1.56% (559453) | PCRX / |
| STACK DAVID M President and CEO | 0.28% (100446) | BIOC / PCRX / |
| Scibetta James S Chief Financial Officer | 0.07% (25118) | PCRX / |
| PACE GARY W | 0.07% (23537) | PCRX / RMD / |
| Williams Kristen Marie CAO and General Counsel | 0.06% (21312) | PCRX / |
| Braunstein Scott SVP, Strategy & Corp. Dev. | 0.06% (20982) | ESPR / PCRX / |
| Jones James B SVP & Chief Medical Officer | 0.05% (16823) | PCRX / |
| Scranton Richard Chief Scientific Officer | 0.04% (13593) | PCRX / |
| Riker Lauren Bullaro Executive Director, Finance | 0.03% (10442) | PCRX / |
| Reinhart Charles A. III Chief Financial Officer | 0.02% (8750) | PCRX / PIP / |
| Markvicka Taunia Vice President, Commercial | 0.02% (8579) | CRMD / PCRX / |
| WINGER DENNIS L | 0.02% (7490) | ARAY / NKTR / PCRX / |
| Kronenfeld Mark A. | 0.02% (6795) | PCRX / |
| LONGENECKER JOHN P PHD | 0.01% (5145) | PCRX / |
| Weiland Robert J. Chief Commercial Officer | 0.01% (4864) | CBAY / PCRX / |
| Greenstreet Yvonne | 0.01% (4845) | ALNY / MC / PCRX / |
| Brege Laura | 0.01% (3845) | ACAD / DCTH / DVAX / PCRX / PETX / PTLA / |
| HASTINGS PAUL J | 0.01% (3518) | OMED / PCRX / PRTO / RLYP / |
UM